Arixtra and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Arixtra (fondaparinux sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Synthroid, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Arixtra. It is created by eHealthMe based on reports of 9,755 people who have side effects when taking Arixtra from the FDA, and is updated regularly.

What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 9,830 Arixtra users. Check the latest studies of Arixtra.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,749 drugs and 2,916 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

9,755 people reported to have side effects when taking Arixtra.
Among them, 70 people (0.72%) have Hypersensitivity.

Among these 70 people:

How long have people been on Arixtra when they have Hypersensitivity? *

What is the gender of people who have Hypersensitivity when taking Arixtra? *

female: 74.63 %
male: 25.37 %

What is the age of people who have Hypersensitivity when taking Arixtra? *

What are other drugs people take besides Arixtra? *

What are other side effects people have besides Hypersensitivity? *

Rashes (redness): 27 people, 38.57%
Itching: 14 people, 20.00%
Dyspnea (difficult or laboured breathing): 13 people, 18.57%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 12 people, 17.14%
Urticaria (rash of round, red welts on the skin that itch intensely): 11 people, 15.71%
Chest Pain: 9 people, 12.86%
Weakness: 8 people, 11.43%
Fatigue (feeling of tiredness): 8 people, 11.43%
Oedema Peripheral (superficial swelling): 8 people, 11.43%
Thrombocytopenia (decrease of platelets in blood): 8 people, 11.43%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 6 people, 8.57%
Thrombosis (formation of a blood clot inside a blood vessel): 5 people, 7.14%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 5.71%
Sleep Disorder: 3 people, 4.29%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 3 people, 4.29%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 4.29%
Multiple Myeloma (cancer of the plasma cells): 2 people, 2.86%
Thrombophlebitis (swelling (inflammation) of a vein caused by a blood clot): 2 people, 2.86%
Anaemia Of Malignant Disease: 2 people, 2.86%
Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 2 people, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arixtra:

Arixtra (9,830 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

Browse all side effects of Arixtra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,749 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,916 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium (the active ingredients of Arixtra) and Arixtra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.